Le Lézard
Classified in: Health, Science and technology
Subject: FDA

Sound Biologics Announces FDA Allowance of its IND Application for PSB205, an Anti-PD-1/CTLA-4 MabPair, in Relapsed and Refractory Solid Tumors


SEATTLE, April 10, 2019 /PRNewswire/ -- Qilu Puget Sound Biotherapeutic Corp. (Sound Biologics), an emerging biotechnology company dedicated to developing next generation antibody combination therapies, today announced that U.S. Food and Drug Administration (FDA) has accepted the Company's Investigational New Drug (IND) application and issued authorization to commence a Phase I First-in-Human Clinical Trial of PSB205 for the treatment of patients with relapsed/refractory solid tumors. PSB205 is an immuno-oncology biotherapeutic that represents the first of a new class of therapeutic modality.  

Sound Biologics (www.soundbiologics.com) is a privately held biotech company specializing in discovery and development of novel oncology biotherapeutics. The company's MabPair technology is a powerful new platform enabling production of two distinct monoclonal antibodies from a single cell line.

PSB205 is a novel bifunctional product that contains a mixture of unique anti-PD-1 and anti-CTLA4 monoclonal antibodies produced by a single cell line via the company's proprietary MabPair technology. MabPair products offer many advantages over bispecific antibodies. The relative ratio of the two antibodies in the MabPair can be well-controlled and each antibody is individually engineered for optimal target coverage, effector function, pharmacokinetics and exposure. PSB205 represents a potentially best-in-class immuno-oncology product that promises to exhibit robust combination activity while being significantly more tolerable to patients than currently approved anti-PD-1/anti-CTLA-4 combinations.

"We're pleased to take this critical step toward providing cancer patients with a better therapeutic option for blockade of two key immunotherapy pathways," said Wei Yan, Chief Executive Officer of Sound Biologics. "PSB205 represents the first product to contain two antibodies expressed from one cell line. We're excited to be the first to explore this innovative approach to biologic combinations and look forward to reviewing the initial clinical data in late 2019."

About Sound Biologics
Qilu Puget Sound Biotherapeutic Corp. (Sound Biologics) is a privately held biotech company specializing in discovery and development of novel oncology biotherapeutics. The company's MabPair technology is a powerful new platform enabling production of two distinct monoclonal antibodies from a single cell line. Products derived via the MabPair platform will offer compelling advantages compared to bispecific antibody products or conventional antibody combinations including full flexibility in choice of different Fc backbones for antibody effector function, streamlined regulatory and clinical development paths, and single-entity pricing power. Sound Biologics is actively sourcing discovery and clinical collaborations while continuing to build a robust internal pipeline. For more information, please visit www.soundbiologics.com.                                                                                                                  

Contact: Sound Biologics
David Meininger PhD, MBA
Corporate Development
408-609-0437
dave@soundbiologics.com

SOURCE Sound Biologics


These press releases may also interest you

at 06:00
iQIYI, Inc. ("iQIYI" or the "Company"), an innovative market-leading online entertainment service in China, recently announced upcoming releases of 60 major drama series and variety shows at its iJOY Conference (the "Conference") held in Shanghai....

at 05:00
This year's topic is Hack the Crisis: Business Tips for Post-Covid Era. The online event is to happen on July 23, 2020. The event will gather ride-hailing entrepreneurs, stakeholders, and experts from around the globe. Speakers will share insights...

at 03:00
MedAlliance has announced enrollment of the first patient in its study of SELUTION SLRtm 014 DEB for the treatment of In-Stent Restenosis (ISR). This is the first DEB accepted by the FDA for its 'Breakthrough Program'. The SELUTION SLR (Sustained...

10 jui 2020
Syniti, a global data solution provider, today announced a continued commitment to accelerating customers' digital transformation with its Global Alliance Partners. In the first six months of 2020, Syniti's revenue with Alliance Partners grew more...

10 jui 2020
Growatt, one of the world's top 5 three-phase string inverter suppliers according to IHS Markit, introduces MAC series of its X generation inverters for three-phase solar PV market in Brazil. The new inverter series provide flexibility to meet the...

10 jui 2020
Technavio has been monitoring the adaptive learning software market and it is poised to grow by $ 384.99 mn during 2020-2024, progressing at a CAGR of over 11% during the forecast period. The report offers an up-to-date analysis regarding the current...



News published on 10 april 2019 at 07:30 and distributed by: